Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease
- PMID: 17934973
- DOI: 10.1080/00365510701663350
Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease
Abstract
Background: Matrix metalloproteinases (MMPs) are important in the atherosclerotic process. The relationship between MMPs and traditional risk factors for cardiovascular disease (CVD) and any influence of lifestyle changes are largely unknown.
Objectives: In a factorial design, we studied the effects of 3 years of dietary counselling and/or n-3 PUFA supplementation (2.4 g/d) on the levels of MMP-9, tissue inhibitor of metalloproteinase (TIMP-1) and pregnancy-associated plasma protein (PAPP-A) in a population of elderly men at high risk of CVD (n = 563, age 70+/-6 years). We further explored the association between these markers and different disease entities, carotid intima media thickness (IMT) and traditional risk factors for CVD.
Results: Smokers had significantly higher levels of MMP-9 (p<0.0001), and TIMP-1 levels were lower in subjects with previous AMI (p = 0.021). MMP-9 was significantly correlated with LDL-C and inversely with HDL-C (both p<0.0001). There were no significant correlations between the measured variables and IMT. Significant reductions in MMP-9 and PAPP-A levels after 36 months were found in all study groups, however, with no between-group differences.
Conclusions: The elevated levels of MMP-9 in smokers and the reduced levels of TIMP-1 in patients with previous AMI reflect an importance of MMPs in the development of CVD. Intervention with diet and/or n-3 PUFA supplementation did not influence the levels of MMP-9, TIMP-1 or PAPP-A in the present population.
Similar articles
-
Serum concentrations of matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1 and alpha2-macroglobulin in healthy subjects after supplementation with different doses of marine n-3 fatty acids.Cell Mol Biol (Noisy-le-grand). 2010 Feb 25;56(1):102-9. Cell Mol Biol (Noisy-le-grand). 2010. PMID: 20196974 Clinical Trial.
-
Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).Am J Hypertens. 2004 Sep;17(9):764-9. doi: 10.1016/j.amjhyper.2004.05.019. Am J Hypertens. 2004. PMID: 15363817 Clinical Trial.
-
The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina.Thromb Res. 2009 Nov;124(5):560-4. doi: 10.1016/j.thromres.2009.04.001. Epub 2009 May 1. Thromb Res. 2009. PMID: 19410278
-
Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.Vasc Med. 2012 Apr;17(2):73-8. doi: 10.1177/1358863X11435979. Epub 2012 Mar 8. Vasc Med. 2012. PMID: 22402936
-
Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.Transl Res. 2007 Mar;149(3):137-44. doi: 10.1016/j.trsl.2006.09.001. Transl Res. 2007. PMID: 17320799
Cited by
-
Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Nov 27;11(11):CD012345. doi: 10.1002/14651858.CD012345.pub3. Cochrane Database Syst Rev. 2018. PMID: 30484282 Free PMC article.
-
Reduced or modified dietary fat for preventing cardiovascular disease.Cochrane Database Syst Rev. 2011 Jul 6;(7):CD002137. doi: 10.1002/14651858.CD002137.pub2. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2012 May 16;(5):CD002137. doi: 10.1002/14651858.CD002137.pub3. PMID: 21735388 Free PMC article. Updated.
-
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Jul 18;7(7):CD003177. doi: 10.1002/14651858.CD003177.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2018 Nov 30;11:CD003177. doi: 10.1002/14651858.CD003177.pub4. PMID: 30019766 Free PMC article. Updated.
-
Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Jul 18;7(7):CD012345. doi: 10.1002/14651858.CD012345.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2018 Nov 27;11:CD012345. doi: 10.1002/14651858.CD012345.pub3. PMID: 30019767 Free PMC article. Updated.
-
The MMP-9 -1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease.PLoS One. 2014 Sep 5;9(9):e106816. doi: 10.1371/journal.pone.0106816. eCollection 2014. PLoS One. 2014. PMID: 25191702 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous